Animal Models of Peripheral Neuropathies

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 262-269

  Höke, Ahmet ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Diabetic autonomic neuropathy; Diabetic neuropathy; HIV associated sensory neuropathy; Human immunodeficiency virus; Toxic neuropathy

Indexed keywords

PACLITAXEL;

ANIMAL MODEL; BRAIN ELECTROPHYSIOLOGY; CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL FEATURE; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; HIV ASSOCIATED DEMENTIA; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SKIN BIOPSY;

ANIMALS; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 84859721816     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0116-y     Document Type: Review

References (119)

1. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591-1597.
2. Clues to diagnosis of peripheral neuropathy: history and examination of the patient. In: Mendell JR, Kissel J, Cornblath DR, eds. Diagnosis and Management of Peripheral Nerve Disorders. New York: Oxford, 2001: 10-29.
3. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007: CD004572.
4. Feldman E. Diabetic neuropathy. Curr Drug Targets 2008; 9: 1-2.
5. Zochodne D. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007; 36: 144-166.
6. Said G. Diabetic neuropathy - a review. Nat Clin Pract Neurol 2007; 3: 331-340.
7. Boulton A, Malik R, Arezzo J, Sosenko J. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486.
8. Zochodne D. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21: 527-533.
9. Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77(suppl 1): S184-S189.
10. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-583.
11. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2009; 6: 638-647.
12. Llewelyn J, Gilbey S, Thomas P, et al. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain 1991; 114(pt 2): 867-892.
13. Dyck P, Lais A, Karnes J, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19: 425-439.
14. Said G, Slama G, Selva J. Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy. Brain 1983; 106(pt 4): 791-807.
15. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977; 40: 1072-1082.
16. Sullivan KA, Lentz SI, Roberts JL Jr., Feldman EL. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 2008; 9: 3-13.
17. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: 91-98.
18. Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 1967; 16: 51-56.
19. Jakobsen J, Lundbaek K. Neuropathy in experimental diabetes: an animal model. Brit Med J 1976; 2: 278-279.
20. Schmidt RE, Matschinsky FM, Godfrey DA, Williams AD, McDougal DB Jr. Fast and slow axoplasmic flow in sciatic nerve of diabetic rats. Diabetes 1975; 24: 1081-1085.
21. Yagihashi S, Kudo K, Nishihira M. Peripheral nerve structures of experimental diabetes rats and the effect of insulin treatment. Tohoku J Exp Med 1979; 127: 35-44.
22. Brown MJ, Sumner AJ, Greene DA, Diamond SM, Asbury AK. Distal neuropathy in experimental diabetes mellitus. Ann Neurol 1980; 8: 168-178.
23. Moore SA, Peterson RG, Felten DL, O'Connor BL. A quantitative comparison of motor and sensory conduction velocities in short- and long-term streptozotocin- and alloxan-diabetic rats. J Neurol Sci 1980; 48: 133-152.
24. Yue DK, Hanwell MA, Satchell PM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 1982; 31: 789-794.
25. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane database of systematic reviews 2007: CD004572.
26. Holland NR, Stocks A, Hauer P, et al. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology 1997; 48: 708-711.
27. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995; 45: 1848-1855.
28. Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 2004; 127(pt 7): 1593-1605.
29. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111.
30. Lauria G, Lombardi R, Borgna M, et al. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Periph Nerv Syst 2005; 10: 202-208.
31. Drel VR, Pacher P, Vareniuk I, et al. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 2007; 569: 48-58.
32. Johnson MS, Ryals JM, Wright DE. Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy. Pain 2008; 140: 35-47.
33. Drel VR, Mashtalir N, Ilnytska O, et al. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006; 55: 3335-3343.
34. Obrosova IG, Ilnytska O, Lyzogubov VV, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 2007; 56: 2598-2608.
35. Cheng HT, Dauch JR, Hayes JM, Yanik BM, Feldman EL. Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. Neurobiol Dis 2012; 45: 280-287.
36. Yamakawa I, Kojima H, Terashima T, et al. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 2011; 301: E844-E852.
37. Stavniichuk R, Drel VR, Shevalye H, et al. Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation. Exp Neurol 2011; 230: 106-113.
38. Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med 2011; 50: 1400-1409.
39. Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 2011; 164: 1410-1420.
40. Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D, Elmlinger M. Treatment with Actovegin(R) improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes 2012; 120(03): 132-138.
41. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-88.
42. Lee JH, McCarty R. Glycemic control of pain threshold in diabetic and control rats. Physiol Behav 1990; 47: 225-230.
43. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL. Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. Pain 1994; 58: 413-420.
44. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 1993; 52: 1049-1055.
45. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998; 76: 151-157.
46. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: Effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996; 68: 293-299.
47. Malmberg AB, Yaksh TL, Calcutt NA. Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci Lett 1993; 161: 45-48.
48. Rossini AA, Williams RM, Mordes JP, Appel MC, Like AA. Spontaneous diabetes in the gnotobiotic BB/W rat. Diabetes 1979; 28: 1031-1032.
49. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology 1972; 90: 1320-1330.
50. Brussee V, Guo G, Dong Y, et al. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes 2008; 57: 1664-1673.
51. Kamiya H, Murakawa Y, Zhang W, Sima AAF. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005; 21: 448-458.
52. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Yorek MA. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab 2009; 11: 223-233.
53. Stevens MJ, Zhang W, Li F, Sima AAF. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004; 287: E497-E505.
54. Sullivan KA, Hayes JM, Wiggin TD, et al. Mouse models of diabetic neuropathy. Neurobiol Dis 2007; 28: 276-285.
55. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994; 57: 153-160.
56. Yamamoto H, Shimoshige Y, Yamaji T, et al. Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats. Neuropharmacology 2009; 57: 403-408.
57. Kvinesdal B, Molin J, Frøland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251: 1727-1730.
58. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-596.
59. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
60. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. NEJM 1992; 326: 1250-1256.
61. McQuay HJ, Tramèr M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-227.
62. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
63. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
64. Ziegler D, Dannehl K, Volksw D, et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients. Diabetes Care 1992; 15: 908-911.
65. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992; 6: 49-57.
66. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995; 45: 773-780.
67. Giachetti A. The functional state of sympathetic nerves in spontaneously diabetic mice. Diabetes 1978; 27: 969-974.
68. Monckton G, Pehowich E. Autonomic neuropathy in the streptozotocin diabetic rat. Can J Neurol Sci 1980; 7: 135-142.
69. Schmidt RE, Nelson JS, Johnson EM, Jr. Experimental diabetic autonomic neuropathy. Am J Pathol 1981; 103: 210-225.
70. Schmidt RE, Dorsey DA, Beaudet LN, et al. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol 2004; 63: 450-460.
71. Wilson HF, Mayer JH, Clarke SA, Tomlinson DR. An examination of autonomic nervous function in genetically diabetic mice. J Auton Pharmacol 1982; 2: 147-153.
72. Schmidt RE, Scharp DW. Axonal dystrophy in experimental diabetic autonomic neuropathy. Diabetes 1982; 31: 761-770.
73. Schmidt RE, Beaudet LN, Plurad SB, Dorsey DA. Axonal cytoskeletal pathology in aged and diabetic human sympathetic autonomic ganglia. Brain Res 1997; 769: 375-383.
74. Schmidt RE, Dorsey DA, Beaudet LN, et al. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am J Pathol 1999; 155: 1651-1660.
75. Schmidt RE, Feng D, Wang Q, et al. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol 2011; 232: 126-135.
76. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46.
77. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol. 2011. doi: 10. 1016/j. critrevonc. 2011. 04. 012.
78. Roytta M, Raine CS. Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 1986; 15: 483-496.
79. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87-90.
80. Cavaletti G, Petruccioli MG, Tredici G, et al. Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int J Tissue React 1991; 13: 151-157.
81. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31: 76-80.
82. Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995; 133: 64-72.
83. Russell JW, Gill JS, Sorenson EJ, Schultz DA, Windebank AJ. Suramin-induced neuropathy in an animal model. J Neurol Sci 2001; 192: 71-80.
84. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317-325.
85. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 1987; 10: 80-84.
86. Apfel SC, Arezzo JC, Lewis ME, Kessler JA. The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice. Ann N Y Acad Sci 1993; 692: 243-245.
87. Roytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 1985; 14: 157-175.
88. Cliffer KD, Siuciak JA, Carson SR, et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998; 43: 46-55.
89. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94: 293-304.
90. Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001; 108: 507-515.
91. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005; 41: 1460-1466.
92. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-257.
93. Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006; 201: 507-514.
94. Xiao WH, Zheng H, Zheng FY, et al. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011; 199: 461-469.
95. Mimura Y, Kato H, Eguchi K, Ogawa T. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 2000; 21: 513-520.
96. Wang MS, Davis AA, Culver DG, Glass JD. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 2002; 52: 442-447.
97. Melli G, Jack C, Lambrinos GL, Ringkamp M, Hoke A. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis 2006; 24: 525-530.
98. Wang MS, Davis AA, Culver DG, et al. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 2004; 127(pt 3): 671-679.
99. Smith SB, Crager SE, Mogil JS. Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 2004; 74: 2593-2604.
100. Hoke A, Cornblath DR. Peripheral neuropathies in human immunodeficiency virus infection. Suppl Clin Neurophysiol 2004; 57: 195-210.
101. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38: 794-796.
102. Pardo C, McArthur J, Griffin J. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6: 21-27.
103. Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003; 54: 287-296.
104. Keswani SC, Chander B, Hasan C, et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003; 53: 57-64.
105. Keswani SC, Jack C, Zhou C, Hoke A. Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci 2006; 26: 10299-10304.
106. Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367: 188-193.
107. Joseph EK, Chen X, Khasar SG, Levine JD. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 2004; 107: 147-158.
108. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci 2004; 20: 2896-2902.
109. Joseph EK, Levine JD. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006; 121: 105-114.
110. Wallace VC, Segerdahl AR, Blackbeard J, Pheby T, Rice AS. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci Lett 2008; 448: 153-156.
111. Wallace VC, Blackbeard J, Pheby T, et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 2007; 133: 47-63.
112. Wallace VC, Blackbeard J, Segerdahl AR, et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 2007; 130(pt 10): 2688-2702.
113. Kennedy JM, Hoke A, Zhu Y, et al. Peripheral neuropathy in lentivirus infection: evidence of inflammation and axonal injury. Aids 2004; 18: 1241-1250.
114. Laast VA, Shim B, Johanek LM, et al. Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am J Pathol 2011; 179: 2337-2345.
115. Ebenezer GJ, Laast VA, Dearman B, et al. Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model. J Comp Neurol 2009; 514: 272-283.
116. Lehmann HC, Chen W, Borzan J, Mankowski JL, Hoke A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol 2011; 69: 100-110.
117. Zhu Y, Jones G, Tsutsui S, et al. Lentivirus infection causes neuroinflammation and neuronal injury in dorsal root ganglia: pathogenic effects of STAT-1 and inducible nitric oxide synthase. J Immunol 2005; 175: 1118-1126.
118. Zhu Y, Antony J, Liu S, et al. CD8+ lymphocyte-mediated injury of dorsal root ganglion neurons during lentivirus infection: CD154-dependent cell contact neurotoxicity. J Neurosci 2006; 26: 3396-3403.
119. Zhu Y, Antony JM, Martinez JA, et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 2007; 130(pt 8): 2011-2023.